Clinical Trials Logo

Clinical Trial Summary

The Academic centre for Malignant Hyperthermia of Masaryk University (ACMHMU) was established in 2021 in Brno, Czech Republic and consists of four academic departments of Medical Faculty of Masaryk University in two tertiary university hospitals, University Hospital Brno and St. Anne Faculty Hospital. These departments collaborated and operated since 2002 and since 2019 is Brno one of the of centre of EMHG (www.emhg.org).


Clinical Trial Description

We evaluated every referral to the MH centre since 2002 then. IVCT results, clinical data, personal and family history and molecular genetic data, have been recorded in an electronic medical record. Potential MHS patients, probands, were investigated according to the European Malignant Hyperthermia Group (EMHG) recommendations using IVCT and/or RYR1 and CACNA1S sequence variant screening. Each proband is a representative of one unrelated family. As the diagnostic guidelines were changing in the time, so was our diagnostic algorithm with the development of new knowledge and methods. Originally before 2015, for each proband or the nearest relative in case that the index case could not be tested, MH must be confirmed/excluded by IVCT. Only with a positive IVCT positive result (MHS, MHEh, MHEc), genetic diagnosis was originated. iIn 2015, a new EMHG guideline for the diagnosis of MH was issued and significantly moved the DNA diagnosis of MH to the forefront and we started to use genetic testing as a first diagnostic step. Not finding the diagnostic variant does not exclude MH susceptibility and IVCT needs to follow for final diagnosis. IVCT has been providing according to the best practise and EMGH guidelines. So far, the genetic diagnosis of MH in the Czech Republic has been in several stages - starting with standard scoring of 33 most common causal diagnostic variants of the RYR1 gene by using multiplex ligation-dependent probe amplification (MLPA) (SALSA MLPA probemix P281-A3/P282-A3 RYR1, MRC Holand). In case of a negative result, direct sequence analysis of the RYR1 and CACNA1S gene sections followed, where the remaining causal diagnostic variants occur. Since 2021 MLPA and direct sequencing of hot spots regions of RYR1 and CACNA1S was routinely replaced by next-generation sequencing (NGS) at the level of a panel of genes associated with neuromuscular diseases (including RYR1, CACNA1S and STAC3). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05036148
Study type Observational
Source Brno University Hospital
Contact Petr Stourac, prof.MD., Ph.D.
Phone 532234404
Email [email protected]
Status Not yet recruiting
Phase
Start date September 1, 2021
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02561598 - A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia
Withdrawn NCT01624558 - Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient N/A
Recruiting NCT04474860 - Gene Mutation Spectrum of Malignant Hyperthermia in China
Active, not recruiting NCT03964870 - Spanish Registry of RYR1 and CACNA1S Polymorphisms
Recruiting NCT04610619 - Multisystem Features of Malignant Hyperthermia or Rhabdomyolysis Related to RYR1 Variants
Terminated NCT02964481 - Malignant Hyperthermia Registry and Genetic Testing